Change over period: —
NSE · ANTHEM
ANTHEM
-4.6% from the 52-week high · +55.5% above the low
Anthem Biosciences Ltd operates in pharmaceutical and biotechnology research, manufacturing, and development. The company delivers innovative healthcare solutions and high-quality products, supporting medical research and patient care across various therapeutic areas.
The short version. ANTHEM reported revenue of ₹594 crore for Sep 2026, up 8.0% from a year earlier. Net profit was ₹211 crore (up 22.0% year on year). Return on equity was 19.4% in Mar 2026. Promoter holding was 71.4% in Sep 2026, down 3.29 points over 6 quarters.
1 · The price
How has the stock traded?
ANTHEM trades 4.6% below its 52-week high and 55.5% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹594 cr.
Sep 2026 net profit of ₹211 cr.
4.1 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|---|---|
| Revenue | 594 | 418 | 611 | 423 | 550 | 540 |
| Net profit | 211 | 120 | 190 | 93 | 173 | 136 |
| Net margin % | 35.6 | 28.7 | 31.1 | 21.9 | 31.5 | 25.1 |
| EPS (₹) | 3.75 | 2.13 | 3.38 | 1.65 | 3.09 | 2.42 |
Annual
| FY2026 | |
|---|---|
| Revenue | 2124 |
| Net profit | 592 |
| Net margin % | 27.9 |
| EPS (₹) | 10.54 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 19.4% in Mar 2026; debt to equity is 0.02.
Profitability · 1 years
Returns and margins
| Mar 2026 | |
|---|---|
| Return on equity % | 19.4 |
| Return on capital % | 26.8 |
| EBITDA margin % | 42.3 |
| Net margin % | 25.9 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 3.29 pts over 6 quarters.
Up 2.29 pts over 6 quarters.
Up 8.49 pts over 6 quarters.
+39 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|
| Promoter | 74.69 | 74.69 | 74.69 | 74.68 | 71.42 | 71.4 | -3.29 |
| FII | 1.5 | 1.67 | 1.36 | 1.28 | 2.58 | 3.79 | +2.29 |
| DII | 3.61 | 7.22 | 7.6 | 11.55 | 13.48 | 12.1 | +8.49 |
| Public | 20.2 | 16.42 | 16.35 | 12.5 | 12.53 | 12.7 | -7.5 |
Mutual fund holdings · Oct 2026
160 schemes hold this stock
121 the month before.
- Motilal Oswal Manufacturing Fund3.97% of NAV
- TATA INDIA PHARMA & HEALTHCARE FUND2.99% of NAV
- HDFC Business Cycle Fund2.97% of NAV
- SBI MNC Fund2.97% of NAV
- HDFC Pharma and Healthcare Fund2.92% of NAV
- Capitalmind Flexi Cap Fund2.67% of NAV
- SBI Healthcare Opportunities Fund2.57% of NAV
- Kotak Healthcare Fund2.17% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ANTHEM are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ANTHEM
What is the ANTHEM share price?
ANTHEM (ANTHEM) last closed at ₹936.80, up 2.46% on the day. Its 52-week range is ₹587.85 to ₹958.15.
What is the market cap of ANTHEM?
ANTHEM has a market capitalisation of about ₹51,484 crore. Its price-to-earnings ratio is 84.7.
How are ANTHEM's latest results?
ANTHEM reported revenue of ₹594 crore for Sep 2026, up 8.0% from a year earlier. Net profit was ₹211 crore (up 22.0% year on year). Return on equity was 19.4% in Mar 2026. Promoter holding was 71.4% in Sep 2026, down 3.29 points over 6 quarters.
Who owns ANTHEM?
As of Sep 2026, shareholding was: Promoter 71.4%, FII 3.79%, DII 12.1%, Public 12.7%.
How many mutual funds hold ANTHEM?
160 mutual fund schemes held ANTHEM in October 2026. That compares with 121 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 25 Jun 2026 · Final Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.